Insmed Inc

Insmed Inc has a negative net equity of -$464.81 million, indicating that its liabilities exceed its assets, and it is operating with a significant long-term debt of $1.35 billion. The company's cash and equivalents amount to $595.73 million, which is insufficient to cover its long-term debt, resulting in a negative net cash position. The company's liquidity is rated as medium, and its current ratio of 1.8 suggests it has enough current assets to cover its current liabilities, but not with a large margin of safety. In terms of profitability, Insmed Inc reported a net loss of $157.09 million and an operating loss of $145.51 million in the latest period. The company's return on equity is 33.8%, which is high in absolute terms but misleading due to the negative equity base. The return on assets is -13.55%, indicating that the company is not generating a positive return on its asset base. The company's gross profit of $58.04 million is significantly lower than its operating and net losses, suggesting high operating expenses and a challenging business environment. Insmed Inc's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no significant geographic diversification mentioned. The company's revenue of $75.50 million is relatively modest, and there is no indication of multiple revenue streams or geographic regions contributing to this figure. The lack of segment and geographic diversification increases the company's exposure to market-specific risks. The company's growth trajectory is uncertain, with no specific revenue growth rates provided in the latest financial data. The operating cash flow is negative at -$184.04 million, and the free cash flow is also negative at -$158.24 million, indicating that the company is not generating sufficient cash from operations to fund its activities. The capital expenditure of -$4.68 million suggests that the company is not investing in new assets, which could limit its future growth potential. The risk assessment for Insmed Inc highlights a medium liquidity risk and a low dilution risk. The company's negative net cash position after subtracting total debt is a key flag, indicating potential liquidity constraints. The dilution risk is low, and there is no indication of significant dilution potential in the near term. The company's financial structure and negative equity position suggest that it may need to raise additional capital, which could involve issuing new shares or taking on more debt. Recent events and filings for Insmed Inc include analyst estimates that are generally positive, with a mean price target of $212.31 and a median price target of $212.00. The mean recommendation from analysts is 1.68, which is close to a "strong buy" rating. There are 7 strong-buy ratings and 15 buy ratings, with no hold ratings, indicating strong investor confidence in the company's future performance.